1. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Issue 10 (October 2017) Authors: Platzbecker, Uwe; Germing, Ulrich; Götze, Katharina S; Kiewe, Philipp; Mayer, Karin; Chromik, Jörg; Radsak, Markus; Wolff, Thomas; Zhang, Xiaosha; Laadem, Abderrahmane; Sherman, Matthew L; Attie, Kenneth M; Giagounidis, Aristoteles Journal: Lancet oncology Issue: Volume 18:Issue 10(2017:Oct.) Page Start: 1338 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗